TikTok father or mother ByteDance hiring for AI drug discovery group – TechCrunch
ByteDance, TikTok’s Chinese parent company is entering the healthcare industry to diversify a business that is dependent on advertising and live streaming sales. The company, which prides itself on content algorithms, has started hiring talent for AI drug discovery in Mountain View, Shanghai and Beijing, the recruiting page shows.
“We are looking for candidates who can join our team and conduct cutting-edge research in drug discovery and manufacturing using AI algorithms,” said a job advertisement.
The Drug Discovery Team, which would like to take on at least five roles including interns, falls under the ByteDance AI Lab. The AI-focused research and development branch was founded in 2016 to serve ByteDance’s content services like the Chinese version of TikTok, Douyin. Unsurprisingly, however, the lab is expanding its reach to include pharmaceuticals, which can also benefit from the machine learning technologies that support short video feeds.
“Given the number of research fields in AI, the applications of these new technologies can be found in all segments of our product portfolio,” states the ByteDance AI Lab website.
All five drug discovery research positions require a doctorate in relevant disciplines such as computer science, mathematics, computational biology, and computational chemistry. Candidates will work on drug development such as design, identification and simulation according to the contributions.
ByteDance cannot be reached immediately for comment.
Other Chinese tech giants have taken similar steps in the healthcare field. Tencent’s own AI-powered drug team, also under the company’s AI Lab, has been actively publishing results since at least August 2019. Baidu planned to raise $ 2 billion for a new biotech startup focused on drug discovery and AI-assisted diagnosis, Reuters reported in September. Huawei has also made drug discovery and medical imaging efforts through its cloud computing unit.